StockWatch
·

Life Insurance Corporation of India Q2 FY27 Results

LICIQ2 FY27 Results
Filing
Result:Good· Market: Down#Broad based#Margin expansion

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue13.4K9.3%16.1%
Total Income13.4K9.3%16.1%
Expenditure1.3K11.5%7.7%
PBT12.2K11.1%19.3%
Net Profit12.1K10.8%20.0%
OPM90.61%1.75pp2.42pp
NPM90.17%1.50pp2.88pp
EPS9.5810.8%40.0%
View full financials

Core revenue (premium/investment income) grew a healthy 16.1% YoY alongside 20% PAT growth and margin expansion (NPM 87.3%→90.2%), a solid above-average quarter for insurance but not a clear standout absent VNB/persistency data to confirm underlying franchise strength.

LIFE INSURANCE CORPORATION OF INDIA · Q2 FY2027 · THE VERDICT

VNB margin hits target, but APE growth stalled—LIC's mixed quarter reveals ULIP's weight

LIC achieved its mid-20s VNB margin guidance at 22.3%, but APE growth ground to 3.21% as ULIP weakness persisted. Profitability expanded, but it's margin-driven, not organic growth.

13 Nov 2026 · 6 min read
VNB margin achieved

22.3%

+470 bps YoY; mid-20s target hit

APE growth

3.21%

Stalled; not accelerating as promised

PAT growth

₹25,568 Cr

+21.5% H1 YoY; solid

Market share (individual)

58.77%

-64 bps YoY; eroding

Life Insurance Corporation of India closed H1 FY2027 with solid margin expansion but tepid volume growth. The quarter reveals the core constraint: ULIP weakness has become a growth limiter that neither operational efficiency nor protection-business gains can yet overcome. VNB margin hit the mid-20s guidance at 22.3%, but APE—the volume metric that drives long-term franchise health—barely grew at 3.21%, contradicting management's call that it would accelerate in Q2+.

What management promised vs. what delivered

Guidance claims vs. H1 FY2027 actual
Prior guidanceH1 FY2027 resultVerdict
VNB margin to improve toward mid-20sAchieved 22.3%; up 470 bps YoY from 17.6%Supported
APE growth to accelerate in Q2+ as ULIP recoversH1 APE growth 3.21% (₹30,696 Cr); ULIP down 40%+Contradicted
Protection business showing strong growthProtection APE +58.59% YoY to ₹157 Cr; new launches liveSupported
Market share stable in individual and groupIndividual 58.77% (down 64 bps YoY); group 70.45% stableOverstated

The profit reconciliation

H1 PAT grew 21.5% to ₹25,568 Cr on premium income up 11.64% to ₹274,269 Cr. But the mix tells the real story. VNB surged 33.95% to ₹6,846 Cr—outpacing premium growth by 3x. LIC is deliberately shifting to higher-margin products (non-PAR savings, pure protection, annuities) even as headline APE stalls. Non-PAR APE share fell to 34.02% from 36.31%, and individual APE growth slowed to 3.5%. The company is defending profitability through product mix, not growing it through volume.

H1 FY27 YoY growth rates, %
-4.799.5123.838.111.64Premium income33.95VNB (Value of New Business)3.21APE growth-0.64Market share (individual)
Margin expansion is real, but it is decoupling from volume. VNB surges 33.95% while APE grows only 3.21%.

Where growth is (and where it is not)

The bright spot: protection. Pure protection APE jumped 58.59% to ₹157 Cr—a high-margin segment where LIC is just starting. New launches (Health Shield, Cancer Cover, Dhara-II) are gaining traction. The base is small, but trajectory is steep; over three years, if protection reaches ₹500 Cr, this becomes a meaningful margin driver. The anchor: ULIP. Individual ULIP APE dropped 40%+ in H1—a market-driven collapse. Management says agents are trained and ready; when equities rally, they will sell again. Until then, ULIP weakness is a ceiling on individual APE. Since individual APE is 56.11% of total, this one segment is capping enterprise growth.

Group APE grew 14% to ₹13,472 Cr—solid—but remains smaller than individual. Annuities ticked up. Non-PAR savings APE rose 35%, yet now represents only 10.7% of individual APE, down from 12%, signalling market share shifting away toward lower-margin term and PAR products.

The market's read: price, ownership, and positioning

LIC trades at ₹399.3, down 56% from its all-time high of ₹918.95. It sits above its 20-day (₹394.26) and 50-day (₹397.53) moving averages but below the 200-day (₹404.3)—neutral technicals. RSI 52.1 shows no momentum. The valuation reflects a market repricing LIC as a mature, margin-driven insurance utility, not a growth franchise. Ownership confirms it: promoter 96.50% (locked in), FII 0.44% (negligible), DII 0.99% (modest). With institutions uninterested and promoter immobile, there is no constituency for a re-rating higher—which matches the business: 22% VNB margin is defensible, but 3.21% APE growth does not command a growth premium.

The bull-bear ledger

  • VNB margin expanded 470 bps to 22.3%; mid-20s guidance achieved

  • PAT growth 21.5% on sound operating momentum; margin leverage real

  • Protection APE surged 58.59%; high-margin growth engine starting

  • Solvency strong at 2.35x vs. 1.5x regulatory minimum

  • APE growth stalled at 3.21% despite acceleration guidance; ULIP not recovering

  • Market share eroded 64 bps to 58.77% in individuals; competitive loss

  • Non-PAR APE share declining (34.02% vs. 36.31%); mix shifting against profitability

  • Regulatory commission caps pending; 91.81% of business via agents at risk

Risks ranked by severity to a holder

What should concern LIC shareholders, prioritized

ULIP de-growth masks APE deceleration

High

H1 APE growth only 3.21%; contradicts acceleration promise. ULIP down 40%+ and market-dependent (zero internal lever). Without recovery, individual APE stays stalled, capping franchise growth.

Distribution commission reform—rates being capped by IRDA

High

Consultation ongoing. LIC relies on agents for 91.81% of new business. Commission cuts could reduce agent productivity and incentive alignment, pressuring APE and share further.

Market share erosion in individuals

Medium

Individual FYPIP share down 64 bps to 58.77% YoY. Private competitors winning in high-margin segments. If trend persists, forces either margin squeeze or volume concessions.

Non-PAR mix compression despite profitability gains

Medium

Non-PAR APE share fell to 34.02% from 36.31%. While non-PAR savings APE +35%, portfolio share shrinking. If trend continues, long-term VNB margin support weakens.

RBC capital framework—guidelines pending finalization

Medium

Final rules unresolved. Solvency ample now at 2.35x, but if guidelines tighten, may require capital raise or constrain dividends/growth.

What the Q&A revealed

Analysts pushed hard on three fronts. First, VNB margin sustainability: Is the 470-bps gain structural or a one-time mix shift? Management cited product interventions and expense controls but gave limited forward detail. Second, ULIP recovery timing: When do agents start selling again? Management deferred to market conditions; agents are trained and positioned but tied to equity sentiment. No timeline. Third, commission cap impact: How much will agent economics suffer? Management offered regulatory assurance that LIC is "uniquely positioned" rather than numbers. The tone was confident but repetitive—management defended positioning without giving investors concrete catalysts.

What changed this quarter

Direction of key metrics

VNB margin

Product mix shift (non-PAR +35%, protection +58.59%) and efficiency gains. Structural; expected to hold or improve H2.

Up 470 bps to 22.3%

APE growth

ULIP down 40%+; individual APE +3.5%, group +14%, protection +58.59%. Mix shifted but volume stalled. Misses acceleration guidance.

Stalled at 3.21%

Market share (individual)

Slow individual growth loses share to faster-growing competitors. Group stable at 70.45%.

Down 64 bps to 58.77%

Protection APE

New product launches gaining traction. Small base but steep trajectory; emerging as margin lever.

Up 58.59% to ₹157 Cr

The debate

What to watch next quarter
  • 1 · APE growth — the real test of franchise health

    3.21% is stalled. Does it re-accelerate to mid-teens, or stay below 5%? If ULIP does not recover and individual APE stays flat, LIC will lose market share while defending margins. That is a losing long-term formula.

  • 2 · IRDA distribution regulation — commission cap finalization

    When do final rules land? What is the cap rate? How much does agent productivity drop? This is the single biggest earnings variable management is not quantifying. Clarity resets the earnings base.

  • 3 · ULIP market recovery — equity volatility dependent

    If market rally continues, ULIP APE could bounce. If equities roll over, ULIP could deepen negative. This is macro-driven; it is the gate to APE re-acceleration.

LIC delivered solid margin expansion and PAT growth, but the underlying story is margin-driven profitability defense, not organic growth. APE stalled at 3.21%, contradicting acceleration guidance. The company executes well on what it controls (product mix, expense ratio, VNB margin) but is hostage to what it does not (ULIP recovery, market share loss, regulatory commission caps).

Rating: Hold. The stock is fairly priced as a steady 12–15% earnings-growth utility. Upside requires APE re-acceleration and ULIP recovery; downside emerges if commission caps squeeze agent economics and market share erosion accelerates. The single number to track is APE growth next quarter: if it stays below 5%, the franchise is in secular decline and should trade at a lower multiple. If it re-accelerates to 10%+, the bull case re-emerges.

Informational and educational content only. Not investment advice.